Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles.

Sha S, Vong LB, Chonpathompikunlert P, Yoshitomi T, Matsui H, Nagasaki Y.

Biomaterials. 2013 Nov;34(33):8393-400. doi: 10.1016/j.biomaterials.2013.06.032. Epub 2013 Jul 27.

PMID:
23896000
2.

An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice.

Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y.

Gastroenterology. 2012 Oct;143(4):1027-36.e3. doi: 10.1053/j.gastro.2012.06.043. Epub 2012 Jul 3.

PMID:
22771506
3.

Indomethacin-loaded redox nanoparticles improve oral bioavailability of indomethacin and suppress its small intestinal inflammation.

Yoshitomi T, Sha S, Vong LB, Chonpathompikunlert P, Matsui H, Nagasaki Y.

Ther Deliv. 2014 Jan;5(1):29-38. doi: 10.4155/tde.13.133.

PMID:
24341815
4.

Reactive oxygen species-scavenging nanomedicines for the treatment of oxidative stress injuries.

Yoshitomi T, Nagasaki Y.

Adv Healthc Mater. 2014 Aug;3(8):1149-61. doi: 10.1002/adhm.201300576. Epub 2014 Jan 30.

PMID:
24482427
5.

Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis.

Vong LB, Yoshitomi T, Morikawa K, Saito S, Matsui H, Nagasaki Y.

J Gastroenterol. 2014 May;49(5):806-13. doi: 10.1007/s00535-013-0836-8. Epub 2013 May 29.

PMID:
23715850
6.

Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.

Vong LB, Yoshitomi T, Matsui H, Nagasaki Y.

Biomaterials. 2015 Jul;55:54-63. doi: 10.1016/j.biomaterials.2015.03.037. Epub 2015 Apr 9.

PMID:
25934452
7.

Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose-response efficacy.

Vong LB, Mo J, Abrahamsson B, Nagasaki Y.

J Control Release. 2015 Jul 28;210:19-25. doi: 10.1016/j.jconrel.2015.05.275. Epub 2015 May 19.

PMID:
25998050
8.

The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles.

Yoshitomi T, Hirayama A, Nagasaki Y.

Biomaterials. 2011 Nov;32(31):8021-8. doi: 10.1016/j.biomaterials.2011.07.014. Epub 2011 Aug 3.

PMID:
21816462
9.

Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat.

Menozzi A, Pozzoli C, Giovannini E, Solenghi E, Grandi D, Bonardi S, Bertini S, Vasina V, Coruzzi G.

Eur J Pharmacol. 2006 Dec 15;552(1-3):143-50. Epub 2006 Sep 16.

PMID:
17069793
10.

Silica-installed redox nanoparticles for novel oral nanotherapeutics - improvement in intestinal delivery with anti-inflammatory effects.

Hossain MA, Yamashita M, Vong LB, Ikeda Y, Nagasaki Y.

J Drug Target. 2014 Aug;22(7):638-47. doi: 10.3109/1061186X.2014.928716. Epub 2014 Jun 23.

PMID:
24955616
11.

Evaluation of the Toxicity and Antioxidant Activity of Redox Nanoparticles in Zebrafish (Danio rerio) Embryos.

Vong LB, Kobayashi M, Nagasaki Y.

Mol Pharm. 2016 Sep 6;13(9):3091-7. doi: 10.1021/acs.molpharmaceut.6b00225. Epub 2016 Jul 25.

PMID:
27186993
12.

Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats.

Satoh H, Hara T, Murakawa D, Matsuura M, Takata K.

Dig Dis Sci. 2010 May;55(5):1264-71. doi: 10.1007/s10620-009-0893-2. Epub 2009 Jul 9.

PMID:
19588248
13.

NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?

Fornai M, Antonioli L, Colucci R, Pellegrini C, Giustarini G, Testai L, Martelli A, Matarangasi A, Natale G, Calderone V, Tuccori M, Scarpignato C, Blandizzi C.

J Pharmacol Exp Ther. 2014 Jan;348(1):86-95. doi: 10.1124/jpet.113.207118. Epub 2013 Oct 17.

14.

Zinc protects against indomethacin-induced damage in the rat small intestine.

Sivalingam N, Pichandi S, Chapla A, Dinakaran A, Jacob M.

Eur J Pharmacol. 2011 Mar 1;654(1):106-16. doi: 10.1016/j.ejphar.2010.12.014. Epub 2010 Dec 24.

PMID:
21185825
15.

Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis.

Eguchi A, Yoshitomi T, Lazic M, Johnson CD, Vong LB, Wree A, Povero D, Papouchado BG, Nagasaki Y, Feldstein AE.

Nanomedicine (Lond). 2015;10(17):2697-708. doi: 10.2217/nnm.15.87. Epub 2015 May 28.

16.

Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats.

Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S.

Gut. 2009 Dec;58(12):1590-6. doi: 10.1136/gut.2008.156596. Epub 2008 Dec 5.

PMID:
19060018
17.

Role of tumor necrosis factor-α in the pathogenesis of indomethacin-induced small intestinal injury in mice.

Fukumoto K, Naito Y, Takagi T, Yamada S, Horie R, Inoue K, Harusato A, Hirata I, Omatsu T, Mizushima K, Hirai Y, Yoshida N, Uchiyama K, Ishikawa T, Handa O, Konishi H, Wakabayashi N, Yagi N, Kokura S, Ichikawa H, Kita M, Yoshikawa T.

Int J Mol Med. 2011 Mar;27(3):353-9. doi: 10.3892/ijmm.2011.602. Epub 2011 Jan 18.

PMID:
21249312
18.

Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats.

Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, Jin D, Umegaki E, Higuchi K.

J Pharmacol Exp Ther. 2010 Feb;332(2):684-9. doi: 10.1124/jpet.109.162933. Epub 2009 Dec 8.

19.

Exacerbation of indomethacin-induced small intestinal injuries in Reg I-knockout mice.

Imaoka H, Ishihara S, Kazumori H, Kadowaki Y, Aziz MM, Rahman FB, Ose T, Fukuhara H, Takasawa S, Kinoshita Y.

Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G311-9. doi: 10.1152/ajpgi.00469.2009. Epub 2010 May 27.

20.

Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility.

Satoh H, Amagase K, Takeuchi K.

J Pharmacol Exp Ther. 2012 Nov;343(2):270-7. doi: 10.1124/jpet.112.197475. Epub 2012 Aug 1.

Supplemental Content

Support Center